Link Silicon Valley
The fastest way to connect to the people, companies and capital of Silicon Valley
Free 30 Day Trial Account
Sign Up | Log In
Search
EARLY STAGE
 
My Lists

Chimera Bioengineering

329 Oyster Point Blvd Suite 300/JLabs
South San Francisco, CA 94080
USA
(310)497-0736
Website Company Summary Management Team
Team

Management: Vlad Hogenhuis (CEO) Gusti Zeiner (co-Fdr, Professor, Stanford University School of Medicine)
Company

Business description: Chimera Bioengineering aspires to control the immune system. By the time a patient is sitting in front of an oncologist, cancer has evaded their immune system. Chimeric antigen receptor T-cells (CARs) are reprogrammed immune cells, hot-wired to circumvent immune-evasion. Clinical trials for CARs against liquid tumor cancers, like acute lymphoblastic leukemia and lymphoma, have shown transformative results for patients unresponsive to standard therapy. However, limited efficacy against solid tumor cancers, life-threatening toxicities, and limited persistence are impediments to these therapies making a wider impact on cancer patients. Chimera Bioengineering solves the challenges of CARs with drug-responsive gene regulators, which allow us to re-program the "software" of the immune system. They design CAR behavior that promises to minimize toxicity, maximize efficacy and extend persistence so that CARs can lead to cures
Capital

Rounds: 2
Recent fundings: Apr 2022   Nov 2016
Capital raised: 6.5M
Last Round: 7.5M
Ownership: Private  
VCs include: Asian Fund For Cancer Research

Last Tweets


 

Last Mentions


Overview
Record updated: Apr 2022
Sector: Medical
Year Founded: 2015
Rounds: 2
Recent fundings: Apr 2022   Nov 2016
Capital raised: 6.5M
Last Round: 7.5M
Ownership: Private